Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.

Lung cancer (Amsterdam, Netherlands) - 1 May 2021

Park Keunchil, Chang Gee-Chen, Curigliano Giuseppe, Lim Wan-Teck, Soo Ross A, Molina-Vila Miguel A, Cattan Valérie, Darville Hélène, Gandossi Eric, Smutna Veronika, Sudey Isabelle, Viteri Santiago

Abstract excerpt

BACKGROUND: MET and AXL dysregulation is reported as a bypass mechanism driving tumour progression in non-small cell lung cancer (NSCLC) with acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). This non-comparative phase I study investigated the combination of gefitinib with S49076, a MET/AXL inhibitor, in advanced EGFR TKI-resistant NSCLC patients with MET and/or AXL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Indoles

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Thiazolidinediones

Source

Identifiers

PMID: 33798902
DOI: 10.1016/j.lungcan.2021.03.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.PMID 33798902Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.Semantic proximity Read ↗

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Semantic proximity Read ↗

Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis.Semantic proximity Read ↗

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung CancerSemantic proximity Read ↗

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Progress on treatment of MET signaling pathway in non-small cell lung cancer.Semantic proximity Read ↗

Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy.Semantic proximity Read ↗

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.Semantic proximity Read ↗

Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.